BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16 | – | 2,300 | +109.1% | 0.00% | – |
| Q2 2023 | $0 | -100.0% | 1,100 | -96.4% | 0.00% | -100.0% |
| Q1 2023 | $44 | +388.9% | 30,346 | +2234.3% | 0.00% | +300.0% |
| Q4 2022 | $9 | -100.0% | 1,300 | -81.2% | 0.00% | 0.0% |
| Q3 2022 | $21,000 | -30.0% | 6,900 | -49.6% | 0.00% | -50.0% |
| Q2 2022 | $30,000 | -90.1% | 13,700 | -77.8% | 0.00% | -87.5% |
| Q1 2022 | $304,000 | -78.1% | 61,692 | -75.8% | 0.02% | -72.4% |
| Q4 2021 | $1,390,000 | +7215.8% | 255,204 | +1991.8% | 0.06% | +5700.0% |
| Q3 2021 | $19,000 | +18.8% | 12,200 | +9.9% | 0.00% | 0.0% |
| Q2 2021 | $16,000 | -81.0% | 11,100 | +9.9% | 0.00% | -75.0% |
| Q1 2021 | $84,000 | +52.7% | 10,100 | +1204.9% | 0.00% | +33.3% |
| Q4 2020 | $55,000 | +2650.0% | 774 | -22.6% | 0.00% | – |
| Q3 2020 | $2,000 | -97.4% | 1,000 | -97.5% | 0.00% | -100.0% |
| Q2 2020 | $76,000 | -62.9% | 39,900 | +57.7% | 0.01% | -54.5% |
| Q1 2020 | $205,000 | – | 25,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |